Keywords
How to Cite
Abstract
Materials and methods. A group of 19 patients with suspected of recurrent growth malignant and benign tumors and postoperative cysts on PET-CT with 13N-ammonium were examined in the postoperative period. The RPH 13N-ammoniа was injected intravenously at the dose of 350-370MBq/m2 of body surface. It is shown, that PET with 13N-ammonia allows to clearly visualize benign and malignant hypervascular tumors, as well as to assess the efficiency of their treatment. The tendency was detected for prevalence of the increased accumulation of 13N-ammonia in benign hypervascular neoplasms of a vascular line as compared to malignant tumors. That is explained by the dependence of the uptake of the drug both upon the degree of tumor vascularization and upon the presence and concentration of glutamine in tumor cells. It is stated in the paper that the level of the uptake of 13N-ammonium in the tumor is in direct ratio to its perfusion and inversely to the degree of its malignancy. In case of effective treatment the level of accumulation of 13N-ammonia in malignant tumors is nonlinearly increased since the rate of metabolic processes is decreased that leads to accumulation of glutamine, however perfusion in the tumor is also nonlinearly decreased. Conclusion. Ultrashort half-life of the radionuclide [13N] (of 9.96 min) and the low radiation exposure that occurs with intravenous introduction of 13N-ammonium create a unique opportunity for diagnosis and assessment of the efficiency of treatment of brain tumors by the method of positron emission tomography.
References
De Grado T.R., Hanson M.W., Turkington T.G. et al. Estimation of myocardial blood flow for longitudinal studies with 13N-labeled ammonia and positron emission tomography//J. NucI. Cardiol. -1996. -Vol. 3 (61). -P 494-507.
Gelbard A.S. et al. Imaging of Spontaneous Canine Tumors with Ammonia and L-Glutamine Labeled with//J. Nucl. Med. -1977. -Vol. 18. -P. 718-723.
Hutchins G.D. Quantitative evaluation of myocardial blood flow with 13N-ammonia//Cardiology. -1997. -Vol. 88(1). -P. 106-115.
Ling L.H., Relicca PA. Assessment of myocardial viability in chronic left ventricular dysfunction//J. Cardiol. -1995. -Vol. 25(4). -P. 199-211.
Nagamachi S., Czernin J., Kim A.S. et al. Reproducibility of measurements of regional resting and hyperemic myocardial blood flow assessed with PET//J. Nucl. Med. -1996. -Vol. 37(10). -P 1626-1631.
Sawado S., Muzic 0., Beanlands R.S.B. et al. Interobserver and interstudy variability of myocardial blood flow and flow-reverse measurement with nitrogen-13 ammonia-labeled positron emission tomography//J. Nucl. Cardiol. -1995. -Vol. 2(5). -P 413-422.
Schelstraete K. et al. Uptake of 11C-aminocyclopentane carboxylic acid (ACPC) and 13N-ammonia in malignant tumors: a comparative clinical study//Nuclear Medicine in Clinical Oncology. -1986. -P. 250-253.
Schelstraete K. et al. Uptake of 13N-ammonia by human tumours as studied by positron emission tomography//The British journal of radiology. -1982. -Vol. 55(659). -P 797-804.
Xiangsong Z., Weian C., Dianchao Y, et al. Usefulness of 13N-NH3 PET in the evaluation of brain lesions that are hypometabolic on 18F-FDG PET//J. Neurooncol. -2011. -Vol. 105. -P. 103-107.
Xiangsong Z., Xinjianb W., Yongc Z. and Weiana C. 13N-NH3: a selective contrast-enhancing tracer for brain tumor//Nuclear Medicine Communications. -2008. -Vol. 29. -P. 1052-1058.
Xinchong Shi, Xiangsong Zhang, Chang Yi, Xiaoyan Wang, Zhifeng Chen, Bing Zhang. The Combination of 13N-Am-monia and 18F-FDG in Predicting Primary Central Nervous System Lymphomas in Immunocompetent Patients//Clin. Nucl. Med. -2013. -Vol. 38. -P 98-102.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2018